Aktas O, Hartung HP. CSI: MS. Tracing optic nerve involvement by standardized optical coherence tomography. Annals of Neurology 2019; 85: 615-617.

Aktas O. Ein Paradigmenwechsel und die Zukunft. In: Berger T, Linnebank M, Wiendl H (eds.) Betaferon® 2013, 25 Jahre Multiple Sklerose Forschung. Springer 2019, in press.

Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Hartung HP, Hefter H. High prevalence of neutralizing antibodies in long-term botulinum neurotoxin treated patients with spasticity or dystonia. Neurology 2019; 92: e48-e54.

Albrecht P, Petzold LA, Lagreze W, Brand BA. OCT retinal layer nomenculature. Author Response. Neurology 2019, in press.

Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, Meuth SG, Seebohm G, Melzer N. An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. Frontiers in Neurology 2019; 10: 178.

Arendt G, Schlonies S, Orhan E, Stüve O. Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience. Journal of Neurovirology 2019; 25: 174-182.

Arendt G. Die HIV-assoziierte Demenz (HAD) in der Ära moderner antiretroviraler Kombinationstherapien (cART). Brandt, Diener, Gerloff (eds.) Der Neurologe & Psychiater 2019, in press.

Arendt G, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Journal of Neurobehavioral HIV Medicine 2019, in press.

Arendt G, Maschke M. HIV-Infektion und AIDS: neurologische Manifestationen. In: Brandt, Diener, Gerloff (eds.) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer Verlag, 6. Aufl., 2019, in press.

Bar-Or A, Giovannoni G, Hartung HP, Pender MP, Steinman L, Khanna R, Maniar T, Croze E, Aftab B, Joshi AJ. Epstein-Barr Virus in Multiple Sclerosis: Emerging Immunotherapies. Trends in Molecular Medicine 2019, in press.

Barkhof F, Kappos L, Wolinsky JS, Li DK, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology 2019, in press.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. Brain Imaging & Behavior 2019, in press.

Berndt C, Engelke AD, Bräutigam L, Lepka, K. Glutaredoxins in the brain. In: Flohé L, (ed.) Glutathione Systems in Health and Disease, CRC Press, 2019, in press.

Beyer F, Samper Agrelo I, Küry P. Do Neural Stem Cells Have a Choice? Heterogenic Outcome of Cell Fate Acquisition in Different Injury Models. International Journal of Molecular Sciences 2019; 20.

Beyer F, Jadasz J, Samper Agrelo I, Schira-Heinen J, Groh J, Manousi A, Bütermann C, Estrada V, Cantone M, Vera J, Vigano F, Dimou L, Muller HW, Hartung HP, Küry P. Heterogeneous fate choice of genetically modulated adult neural stem cells in grey and white matter of the central nervous system. Glia 2019, in press.

Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology 2019; 92 :e2232-e2239.

Bovis F, De Stefano N, Steinerman JR, Knappertz V, Sormani MP. Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. Multiple Sclerosis 2019, in press.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; The BEYOND and BENEFIT Study Groups. Effect of HLA-DRB1 alleles and genetic variants on the evelopment of neutralizing antibodies to interferon beta in he BEYOND and BENEFIT trials. Multiple Sclerosis Journal 2019; 25: 565-573.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh S; on behalf of the SYNERGY study investigators. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology 2019; 18: 845-856.

Cantone M, Küspert M, Reiprich S, Lai X, Eberhardt M, Göttle P, Beyer F, Azim K, Küry P, Wegner M, Vera J. A gene regulatory architecture that controls region-independent dynamics of oligodendrocyte differentiation. Glia 2019; 67: 825-843.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology 2019; 18: 185-197.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis 2019; 25: 601-609.

Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdová EK, Cree BA, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; for the RADIANCE Trial Investigators. Efficacy and safety of the sphingosine 1-phosphate receptor modulator ozanimod or interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a randomised 24-month phase 3 clinical trial. Lancet Neurology 2019, in press.

Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdová EK, Cree BA, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; for the SUNBEAM Study Investigators. Efficacy and safety of the sphingosine 1-phosphate receptor modulator ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a randomised, ≥12-month, phase 3 trial. Lancet Neurology 2019, in press.

Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology 2019; 32: 365-377.

Cree BAC, Bennett JL, Kim HJ, Weinshenker B, Pittock S, Wingerchuk D, Fujihara K, Paul F, Cutter G, Marihnier R, Green AJ, Aktas O, Hartung HP, Drappa J, Barron G, Madani S, Ratchford J, She D, Cimbora D, Katz E; on behalf of the N-MOmentum study investigators. A Randomized, Placebo-Controlled, Double-Blind, Phase 2/3 Trial of Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder: Results of the N-MOmentum Study. Lancet 2019 in press.

Cruz-Herranz A, Dietrich M, Hilla AM, Yiu HH, Levin MH, Issberner A, Cordano C, Lehmann-Horn K, Balk LJ, Aktas O, Ingwersen J, Hartung HP, Zamvil SS, Fischer D, Albrecht P, Green AJ. Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation 2019, in press.

Cwik JC, Vahle N, Woud ML, Potthoff D, Kessler H, Sartory G, Seitz RJ. Reduced gray matter volume in the left prefrontal, occipital, and temporal regions as predictors for posttraumatic stress disorder: a voxel-based morphometric study. European Archives of Psychiatry and Clinical Neuroscience 2019, in press.

Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. New England Journal of Medicine 2019 16; 380: 1906-1917.

Dietrich M, Hecker C, Hilla A, Cruz-Herranz A, Hartung HP, Fischer D, Green A, Albrecht P. Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. Journal of Visualized Experiments - JoVe 2019; 143. Dietrich M, Aktas O, Hartung HP, Albrecht P. Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. Current Opinion in Neurology 2019; 32: 346-357.

Ferrea S, Saleh A, Wojtecki L, Schnitzler A, Südmeyer M. Diabetic hemichorea-hemiballism – Case report of a patient with endurig striatal lesion. Basal Ganglia 2019, in press.

Fischer D, Klaus A, Ray DE. Toxikologie des Nervensystems. In: Marquardt H, Schäfer S, Barth H (eds.) Toxikologie. 3. Aufl., Wissenschaftliche Verlagsgesellschaft Stuttgart, 2019, in press.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Hartung HP, Kremer D. Managing risks with immune therapies in multiple sclerosis. BioDrugs 2019, in press.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D. Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety 2019; 42: 633-647.

Förster M, Graf J, Mares J, Aktas O, Hartung HP, Kremer D. Drug Treatment of Clinically Isolated Syndrome. CNS Drugs 2019; 33: 659-676.

Foley FW, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Wattjes MP, Schippling S, Koelbach R, Pleimes D, Wicklein EM, Penner IK. Cognitive outcomes at the 11-year follow-up of the BENEFIT study: Impact of early MS treatment with interferon beta-1b. Multiple Sclerosis and Related Disorders 2019, in press.

Garcia Bonitto JR, Carra A, Cárcamo C, Correa P, Fragoso Y, Guerra Posada C, Hartung HP, Macias Islas M, Montañés P, Novarro N, Orozco G, Rodriguez V, Steinberg J, Vizcarra D. Latin-American forum of experts in multiple sclerosis updated management recommendations for multiple sclerosis in Latin America. Journal of the Neurological Sciences 2019, in press.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis. Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology 2019; 76: 841-849.

Gliem M, Krammes K, Liaw L, van Rooijen N, Hartung HP, Jander S. Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia 2019, in press.

Goettle P, Förster M, Gruchot J, Kremer D, Hartung HP, Perron H, Küry P. Rescuing the negative impact of human endogenous retrovirus envelope protein on 1 oligodendroglial differentiation and myelination. Glia 2019; 67: 160-170.

Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs 2019; 33: 61-78.

Graf J, Schwitalla JC, Albrecht P, Veltkamp R, Berlit P, Hartung HP, Aktas O, Kraemer M. Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series. Journal of Neurology 2019; 266: 1153-1159.

Graf J, Ingwersen J, Lepka K, Albrecht P, Hartung HP, Ringelstein M, Aktas O. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. Acta Neurologica Scandinavica 2019, in press

Groiss SJ, Butz M, Baumgarten T, Füllenbach N-D, Häussinger D, Schnitzler A. Stage dependent alteration of cortical excitability in patients with hepatic encephalopathy. Clinical Neurophysiology 2019; 130: 911-916.

Gross J, Kujala J, Salmelin R, Schnitzler A. Non-invasive functional tomographic connectivity analysis with magnetoencephalography. In: Kringelbach M, Hansen P, Salmelin R (eds.) Magnetoencephalography. An introduction to methods. Oxford University Press, Oxford, 2019, in press.

Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D. The Molecular Basis for Remyelination Failure in Multiple Sclerosis. Cells 2019; 8.

Gruchot J, Kremer D, Küry P. Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses. Frontiers in Genetics 2019; 10: 655.

Haas J, Jeffery D, Silva D, Meier D, Meinert R, Cohen J, Hartung HP. Early swith to fingolimod reduces rates of severe relapses over the long term: post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis & Related Disorders 2019, in press.

Hardmeier M, Jacques F, Albrecht P, Bousleiman H, Schindler C, Leocani L, Fuhr P. Multicentre assessment of motor and sensory evoked potentials in multiple sclerosis: reliability and implications for clinical trials. Multiple Sclerosis Journal – Experimental, Translational and Clinical 2019; 5: 2055217319844796.

Hartmann CJ, Fliegen S, Groiss SJ, Wojtecki L, Schnitzler A. An update on best practice of deep brain stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders 2019; 12:1756286419838096.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study. European Journal of Neurology 2019, in press.

Hartung HP, Graf J, Kremer D. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology 2019, in press.

Hartung HP, Graf J, Aktas O, Mares J, Barnett MH. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. Current Opinion in Neurology 2019; 32: 327-337.

Hartung HP, Matthews V, Ross AP, Pitschnau-Michel D, Thalheim C, Ward-Abel N; on behalf of the Multiple Sclerosis-Nurse Empowering Education (MS-NEED) Study Group. Disparities in nursing of multiple sclerosis patients – results of a European nurse survey. Multiple Sclerosis Journal 2019, in press.

Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, McManus D, Schneble HM, Prochet H, Glanzman R, Lambert E, Francis G, Curtin F, Barkhof F. Efficacy and safety of temelimab, an antibody antagonist of the Human Endogenous Retrovirus type-W env protein, in participants with relapsing remitting multiple sclerosis: a double-blind, randomised, placebo-controlled phase 2b clinical trial. Lancet Neurology 2019, in press.

Hassan SS, Baumgarten T, Ali AW, Füllenbach N-D, Jördens, M, Butz M, Häussinger D, Schnitzler A, Groiss SJ. Cerebellar inhibition in hepatic encephalopathy – a transcranial magnetic stimulation study. Clinical Neurophysiology 2019; 130: 886-892.

Havrdova EK, Bar-Or A, Hartung HP, Schippling S, Rakhade S, Ross L, Tornatore C. A Phase 2 Randomized Clinical Study of Vatelizumab in Relapsing Remitting Multiple Sclerosis. Annals of Clinical and Translational Neurology 2019, in press. Heckel M, Kieseier BC, Schaper J, Mayatepek E, Rosenbaum T. Mitoxantrone as rescue therapy in two children with worsening multiple sclerosis. Journal of Pediatric Neurology 2019, in press.

Hensel L, Hoffstaedter F, Caspers J, Michely J, Mathys C, Heller J, Eickhoff CR, Reetz K, Südmeyer M, Fink GR, Schnitzler A, Grefkes C, Eickhoff SB.Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease. Cerebral Cortex 2019; 29: 383-396.

Herrmann AK, Wüllner V, Moos S, Graf J, Chen J, Kieseier B, Kurschus FC, Albrecht P, Vangheluwe P, Methner A. Dimethyl fumarate alters intracellular Ca2+ handling in immune cells by redox-mediated pleiotropic effects. Free Radical Biology & Medicine 2019; 141: 338-347.

Hilla A, Fischer D. Studying the Role of Microglia in Neurodegeneration and Axonal Regeneration in the Visual System. Bio-Protocol 2019, in press. Hirschmann J, Abbasi O, Storzer L, Butz M, Hartmann CJ, Wojtecki L, Schnitzler A. Longitudinal recordings reveal transient increase of alpha/low-beta power in the subthalamic nucleus associated with the onset of Parkinsonian rest tremor. Frontiers in Neurology 2019; 10: 145.

Ingwersen J, de Santi L, Wingerath B, Graf J, Koop B, Schneider R, Hecker C, Schröter F, Bayer M, Engelke AD, Dietrich M, Albrecht P, Hartung HP, Annunziata P, Aktas O, Prozorovski T. Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. Journal of Neurochemistry 2019, in press.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology 2019; 326: 19-27.

Kaschner MG, Lande R, Rubbert C, Caspers J, Lee JI, Gliem M, Jander S, Turowski B.Predictors for basal ganglia viability after mechanical thrombectomy in proximal middle cerebral artery occlusion. Clinical Imaging 2019; 57: 1-6.

Kaschner MG, Weiss D, Rubbert C, Lee JI, Gliem M, Jander S, Ivan V, Kraus B, Turowski B, Caspers J. One-year single-center experience with the Aperio thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome. Neurological Sciences 2019; 40: 1443-1451.

Kaschner MG, Rubbert C, Caspers J, Karsten J, Kraus B, Lee JI, Gliem M, Jander S, Turowski B. A Retrospective Single-Center Case Series of Direct Aspiration Thrombectomy as First-Line Approach in Ischemic Stroke and Review of the Literature. Journal of Stroke andCerebrovascular Diseases 2019; 28: 640-648.

Kieseier BC, Wiendl H. Schädigungsmechanismen bei Multipler Sklerose. In: Zettl U, Mix E (eds.) Multiple Sklerose. Springer, Berlin, 2019, in press.

Kieseier BC. Entzündungsmediatoren als biologische Marker – Zytokine, Chemokine, Adhäsionsmoleküle und Metalloproteasen. In: Berger T (ed.) Biologische Marker für Diagnostik, Prognose und Therapie bei MS. Uni-Med Verlag, Bremen, 2019, in press.

Kieseier BC, Wiendl H. Therapie der Multiplen Sklerose – Aktuelles therapeutisches Vorgehen und Perspektiven. Uni-med Verlag, Bremen, 2019, in press.

Kieseier BC, Wiendl H. Corroborating the orale therapeutic pathway in multiple sclerosis – new evidence for teriflunomide (Editorial) Lancet Neurology 2019, in press.

Kleiser R, Nickel N, Seitz RJ, Trenkler J, Wurm G. Brain Tumors: Clinical Applications of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging. In: Tumors of the Central Nervous System. Springer, Heidelberg, Chapter 20, 2019, in press.

Koy A, Bockhorn N, Kühn AA, Schneider GH, Krause P, Lauritsch K, Witt K, Paschen S, Deuschl G, Krauss JK, Saryyeva A, Runge J, Borggraefe I, Mehrkens JH, Horn A, Vesper J, Schnitzler A, Siegert S, Freilinger M, Eckenweiler M, Coenen VA, Tadic V, Voges J, Pauls KAM, Wirths J, Timmermann L, Hellmich M; GEPESTIM consortium. Adverse events associated with deep brain stimulation in patients with childhood-onset dystonia. Brain Stimulation 2019; 12: 1111-1120.

Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P. Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. Journal of Neurology 2019; 266: 1421-1428.

Kremer D, Akkermann R, Küry P, Dutta R. Current advancements in promoting remyelination in multiple sclerosis. Multiple Sclerosis 2019; 25: 7-14.

Kremer D, Göttle P, Flores-Rivera J, Hartung HP, Küry P. Remyelination in multiple sclerosis: from concept to clinical trials. Current Opinion in Neurology 2019; 32: 378-384.

Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Jang JH, Xu YK, Volsko C, Dutta R, Trapp B, Perron H, Hartung HP, Küry P. pHERV-W envelope protein fuels microglial cell-dependent neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2019; 116: 15216-15225.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis 2019; 25: 591-600.

Lee JI, Gemerzki L, Boerker L, Guthoff R, Aktas O, Gliem M, Jander S, Hartung HP, Albrecht P. No alteration of optical coherence tomography and multifocal visual evoked potentials in eyes with symptomatic carotid artery disease. Frontiers in Neurology 2019; 10: 741.

Levin E, Leibinger M, Gobrecht P, Hilla A, Andreadaki A ,Fischer D. Muscle LIM Protein is expressed in the injured adult CNS and promotes Axon Regeneration. Cell Reports 2019; 26: 1921-1932.

Lin Y, Schulze V, Brockmeyer M, Parco C, Karathanos A, Heinen Y, Gliem M, Hartung HP, Antoch G, Jander S, Turowski B, Perings S, Malte Kelm K, Wolff G. Endovascular thrombectomy as a means to improve survival in acute ischemic stroke – A Meta-Analysis. JAMA Neurology 2019; 76: 850-854.

Lindenberg R, Seitz RJ. Impact of white matter damage after stroke. In: Neuroimaging / Book 1. Intech Publisher, 2019, in press.

Logmin K, Moldovan AS, Elben S, Schnitzler A, Groiss SJ. Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy. Journal of Neurology 2019; 266: 1031-1033.

Manoucheri N, Zhang Y, Salter A, Hartung HP, Hemmer B, Segal BM, Cutter G, Stϋve O. Clinical trials in multiple sclerosis: Prospective future trial designs. Therapeutic Advances in Neurological Disorders 2019; 12:1756286419847095.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System 2019; 24: 48-55.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra study.Journal of the Peripheral Nervous System 2019; 24: 72-79.

Muñoz-Esquivel J, Göttle P, Aguirre-Cruz L, Flores-Rivera J, Corona T, Reyes-Terán G, Küry P, Torres KJ. Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. ASN Neuro 2019, in press.

Nessler S, Hemmer B. Multiple Sklerose und andere demyelinisierende Erkrankungen. In: Klockgether T, Dodel R (eds.) Kurzlehrbuch Neurologie 2019, in press. Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H. Prominent T-Cell Responses against the Acetylcholine Receptor ε Subunit in Myasthenia Gravis. Neurology Research International 2019, in press.

Nikolov P, Hassan SS, Aytulun A, Hartmann CJ, Kohlhase J, Schnitzler A, Albrecht P, Minnerop M, Groiss SJ. Cerebellar Involvement in DYT-THAP1 Dystonia. Cerebellum 2019, in press.

Palaima P, Chamova T, Jander S, Mitev V, Van Broeckhoven C, Tournev I, Peeters K, Jordanova A. Peripheral myelin protein 2 - a novel cluster of mutations causing Charcot-Marie-Tooth neuropathy. Orphanet Journal of Rare Diseases 2019; 14: 197.

Paloutzian RF, Seitz RJ, Angel HF. The Process of Believing and Psychiatric Symptoms. Religion, Brain & Behavior 2019, in press. Penner IK. Kognitive Störungen bei Multipler Sklerose: Wirklich weiche Symptome? Info Neurologie & Psychiatrie 2019, in press.

Penner IK, Hartung HP. The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. Brain 2019, in press.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Scleerosis 2019; 25: 1273-1288.

Prozorovski T, Ingwersen J, Lukas D, Göttle P, Koop B, Graf J, Schneider R, Franke K, Schumacher S, Britsch S, Hartung HP, Küry P, Berndt C, Aktas O. Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. Neuroscience Letters 2019; 704: 116-125.

Pust GEA, Pöttgen J, Randerath J, Lau S, Heesen C, Gold SM, Penner IK. In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients. Journal of Neurology 2019; 266: 1663-1673.

Rieckmann P, Schwab M, Pöhlau D, Penner IK, Wagner T, Schel E, Bayas A. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart®. Advances in Therapy 2019; 36: 175-186.

Ringelstein M, Harmel J, Zimmermann H, Brandt AU, Paul F, Haarmann A, Buttmann M, Hümmert MW, Trebst C, Schroeder C, Ayzenberg I, Kleiter I, Hellwig K, Havla J, Kümpfel T, Jarius S, Wildemann B, Rommer P, Weber MS, Pellkofer H, Röpke L, Geis C, Retzlaff N, Zettl U, Deppe M, Klotz L, Young K, Stellmann JP, Kaste M, Kermer P, Marouf W, Lauda F, Tumani H, Graf J, Klistorner A, Hartung HP, Aktas O, Albrecht P; on behalf of the Neuromyelitis optica study group (NEMOS). Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 2019, in press.

Rivera FJ, Kraus J, Steffenhagen C, Küry P, Weidner N, Aigner L. Remyelination in multiple sclerosis: The therapeutic potential of neural and mesenchymal stem/progenitor cells. Current Signal Transduction Therapy 2019, in press. Rivera FJ, de la Fuente AG, Zhao C, Silva ME, Gonzalez GA, Wodnar R, Feichtner M, Lange S, Errea O, Priglinger E, O'Sullivan A, Romanelli P, Jadasz JJ, Brachtl G, Greil R, Tempfer H, Traweger A, Bátiz LF, Küry P, Couillard-Despres S, Franklin RJM, Aigner L. Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia 2019; 67: 1510-1525.

Rubbert C, Mathys C, Jockwitz C, Hartmann CJ, Eickhoff SB, Hoffstaedter F, Caspers S, Eickhoff CR, Sigl B, Teichert NA, Südmeyer M, Turowski B, Schnitzler A, Caspers J. Machine-learning identifies Parkinson's disease patients based on resting-state between-network functional connectivity. British Journal of Radiology 2019; 92: 20180886.

Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P. Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. FASEB Journal 2019; 33: 4703-4715.

Schönfeld LM, Wojtecki L. Beyond Emotions: Oscillations of the Amygdala and Their Implications for Electrical Neuromodulation. Frontiers in Neuroscience 2019; 13: 366.

Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Halbig T, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari H, Barbe M, Fink G, Kuehn A, Kupsch A, Schneider G-H, Seigneuert E, Fraix V, Kistner A, Chaynes P, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltete D, Damier P, Derkinderen P, Sixel-Doering F, Trenkwalder C, Gharagaghi A, Wachter T, Weiss D, Pinsker M, Regis J-M, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto J-L, Agid Y, Vidalhet M, Timmermann L, Deuschl G Quality of life predicts outcome of deep brain stimulation in early Parkinson’s disease. Neurology 2019; 92: e1109-e1120.

Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Current Opinion in Neurology 2019; 32: 305-312.

Seitz RJ, Paloutzian RF, Angel HF. Believing is representation mediated by the dopamine brain system. European Journal of Neuroscience 2019; 49: 1212-1214.

Seitz RJ, Meisel S, Moll M, Wittsack HJ, Junghans U, Siebler M. Impact of the MRI “Perfusion-Diffusion Mismatch” for thrombolysis in stroke. Neurology 2019, in press.

Seitz R, Vracotas N, Bechard-Evans L, King S, Abadi S, Joober R, Shah JL, Malla AK, Pruessner M. The Trier Social Stress Test in first episode psychosis patients: Impact of perceived stress, protective factors and childhood trauma. Psychoneuroendocrinology 2019; 105: 155-163.

Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurology 2019; 19: 190.

Stettner M, Albrecht P, Derksen A, Hartmann C, Turowski B, Neuen-Jacob E, Hartung HP, Kieseier B, Arendt G. Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis. BMJ Case Reports 2019, in press.

Stöckel A, Paassen B, Dickfelder R, Göpfert JP, Brazda N, Müller HW, Cimiano P, Hartung M, Klinger R. SCIE: information extraction for spinal cord injury preclinical experiments – a webservice and open source toolkit. bioRxiv 2019, in press

Tezayak O, Rosenthal D, Hefter H. Mild gait impairment in long-term treated patients with neurological Wilson's disease. Annals of Translational Medicine 2019; 7: S57.

Torres KJ, Aguirre-Cruz L, Göttle P, Ziegler B, Muñoz Esquivel J, Flores-Rivera J, Reyes-Terán G, Corona T, Küry P. Cultivo de células del sistema nervioso. Cultivo Primario de Oligodendrocitos de Cerebro 2019, in press.

Trenado C, Elben S, Petri D, Hirschmann J, Groiss SJ, Vesper J, Schnitzler A, Wojtecki L. Combined Invasive Subcortical and Non-invasive Surface Neurophysiological Recordings for the Assessment of Cognitive and Emotional Functions in Humans. Journal of Visualized Experiments 2019, in press.

Urban P, Jacobi C, Jander S. Therapiestandards und individualisierte Therapie bei der Myasthenia gravis. Aktuelle Neurologie 2019, in press.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies IS; on behalf of the PATH study group. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurology, Neuroimmunology & Neuroinflammation 2019; 6: e590.

Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC; IGOS Consortium. Current treatment practice of Guillain-Barré syndrome. Neurology 2019; 93: e59-e76.

Vogel F, Hemmer B. Liquorzirkulationsstörungen. In: Klockgether T, Dodel R (eds.) Kurzlehrbuch Neurologie. 2019, in press. Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, Fraering PC, Wirths O, Weggen S. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. Acta Neuropatholgica 2019; 137: 239-257.

Warnke C, Hartung HP. Challenging a concept: Pulsed treatment regimen-No risk of PML? Multiple Sclerosis 2019; 25: 1076-1078.

Warnke C, Hartung HP. Big data in MS – what can we learn from large international observational studies such as MSBase? Multiple Sclerosis 2019, in press.

Weiss D, Kraus B, Rubbert C, Kaschner M, Jander S, Gliem M, Lee JI, Haensch CA, Turowski B, Caspers J. Systematic evaluation of computed tomography angiography collateral scores for estimation of long-term outcome after mechanical thrombectomy in acute ischaemic stroke. The Neuroradiology Journal 2019; 32: 277-286.

Wiendl H, Kieseier BC. Fragen und Antworten zur Neuroimmunologie. Verlag Hans Huber, Bern, 2019, in press.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. Journal of Neurology, Neurosurgery & Psychiatry 2019; 90: 44-46.

Wojtecki L, Schnitzler A. Movement disorders. In: Azari N, et al. (eds.) Encyclopedia of Sciences and Religions. Thieme, 2019, in press.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology 2019; 18: 259-268.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis 2019, in press. Zeus T, Jander S. Akutes Koronarsyndrom und Schlaganfall - interdisziplinäres Management. Aktuelle Kardiologie 2019, in press.

MediathekInformation und Wissen
LageplanSo finden Sie uns